PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
May 1, 2025 – Clinical Trials, Drug Discovery, Other, Pharmaceutical – American Thoracic Society International Conference, PureTech Health, biotherapeutics, conferences and events, idiopathic pulmonary fibrosis
- Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF)
- Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development.
1 May 2025 — Massachusetts, US — PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will deliver a late-breaking oral presentation at the upcoming American Thoracic Society (ATS) International Conference, taking place in San Francisco, California, from May 16-21, 2025.
The presentation will highlight data from the recently completed Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), which demonstrated unprecedented efficacy outcomes in patients living with idiopathic pulmonary fibrosis (IPF), including the potential to stabilize lung function decline at 26 weeks while maintaining safety and tolerability.
“The Phase 2b ELEVATE IPF trial results represent a major advancement for the treatment of IPF,” said Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer of PureTech. “Deupirfenidone demonstrated the potential to stabilize lung function decline over 26 weeks as a monotherapy—something not achieved by marketed or investigational IPF therapies, to our knowledge. The additional data we plan to highlight at ATS provide further confidence in the robust and durable efficacy and favorable tolerability of deupirfenidone. We believe deupirfenidone has the potential to set a new standard of care and make a transformative difference for patients living with this devastating disease.”
PureTech is targeting a meeting with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the Phase 2b trial and align on a potential registrational pathway, with the goal of initiating a Phase 3 trial by the end of 2025. PureTech anticipates providing further guidance later this year following the finalization of the trial design and FDA interactions.
Details of the oral presentation are as follows:
Title: Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial
Presenter: Toby Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California
Session: C93 – Advances in interstitial lung disease and pulmonary hypertension: uncovering novel mechanisms, targeted therapies, and personalized approaches
Date and Time: May 20, 2025, 2:15 PM Pacific Time
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit www.puretechhealth.com
